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GABAergic interneurons control neuronal excitability, integration, and plasticity. Further,
they regulate the generation of temporal synchrony and oscillatory behavior among net-
works of pyramidal neurons. Such oscillations within and across neural systems are
believed to serve various complex functions, such as perception, movement initiation, and
memory. Alterations in the development of GABAergic circuits have been implicated in
various brain diseases with neurodevelopmental origin. Here, we highlight recent stud-
ies suggesting a role for alterations of GABA transmission in the pathophysiology of
two neurodevelopmental diseases, schizophrenia, and autism. We further discuss how
manipulations of GABA signaling may be used for novel therapeutic interventions.
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Cortical neural networks consist of broadly two classes of neu-
rons: excitatory projection neurons, primarily using glutamate as
neurotransmitter, and inhibitory local-circuit interneurons, com-
prising of about 20% of all cortical neurons, and primarily using
gamma-amino butyric acid (GABA) as a neurotransmitter. The
last few years have seen a steep increase in our knowledge of the
function of GABAergic interneurons. Cortical interneurons have
been shown to play a vital role in modulating neuronal excitability
(Swadlow, 2003), integration (Pouille and Scanziani, 2001), and in
the generation of temporal synchrony and oscillation among net-
works of glutamatergic neurons (Klausberger and Somogyi, 2008).
In addition, GABAergic interneurons contribute to almost all fun-
damental processes of cortical development; from neuronal pro-
liferation,migration, and differentiation to experience-dependent
reﬁnement of local cortical circuits (Owens and Kriegstein, 2002;
Hensch, 2005; Sernagor et al., 2010).
These ﬁndings have prompted a change in the way we view the
role of GABAergic cells in cortical development and processing.
Traditionally,GABAergic interneuron function has been described
simply as “inhibition” of neuronal activity, similar to a trafﬁc ofﬁ-
cer who signals simply to let cars stop or go; however it is now clear
that the picture is much more complex. We may instead compare
GABAergic interneuron function to that of a conductor of a sym-
phony orchestra, whose role is to structure and coordinate the
overall musical performance and interpretation of the individual
players. Without proper direction, the orchestra cannot produce
the right melody.
Considering the multifaceted role played by GABAergic cells in
the development, function, and plasticity of cortical networks, it
is straightforward to assume that any disturbance in the develop-
ment of GABAergic interneurons, due to either genetic or epige-
netic factors,will strongly affect brain function. Indeed,disruption
of GABAergic circuit function has been implicated in various
neurodevelopmental and psychiatric disorders including schizo-
phrenia (Gonzalez-Burgos et al., 2011), autism (LeBlanc and Fagi-
olini, 2011),mental retardation (Cramer et al., 2010), and epilepsy
(Rossignol, 2011).Ourunderstanding of themechanismsunderly-
ing development of GABAergic interneurons have started to reveal
speciﬁc molecular and cellular substrates potentially affected in
neurodevelopmental disorders. Further, selective modulation of
inhibitory networks is being currently investigated as a tool to
re-introduce plasticity and therefore facilitate the restoration of
normal function to the diseased brain.
This review will summarize some of the compelling evidence
on the role of alterations in GABAergic neuron function in the
etiology of two neurodevelopmental disorders, schizophrenia, and
autism.Anexhaustive reviewof the genetic causes of schizophrenia
and autism is beyond the scope of this paper, and several excel-
lent reviews have already been published on these topics. We will
further focus on and discuss recent efforts to modify GABAergic
transmission as a targeted therapeutic approach to re-introduce
plasticity in the brain.
CORTICAL INTERNEURON DIVERSITY – A CONTINUOUS
CHALLENGE
Before describing evidence linking GABAergic dysfunction to
neurodevelopmental diseases, we would like to stress that our
understanding of GABAergic interneuron function in normal and
pathological conditions is challenged by their startling hetero-
geneity. Indeed different interneuron subtypes display distinctly
different morphology, physiological properties, connectivity pat-
terns, and vary in their biochemical composition (Markram
et al., 2004). Such complexity makes it difﬁcult to establish a
broad consensus regarding a generalized classiﬁcation scheme of
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interneuron subtypes. In parallel however, several studies have sin-
gled out multiple criteria to distinguish between major interneu-
ron groups. One criterion for instance is the expression of calcium
binding proteins such as parvalbumin (PV), calbindin (CB), or
calretinin (CR) and/or neuropeptides such as somatostatin (SST),
vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), or
cholecystokinin (CCK). Such analysis has shown that the cortex
has three largely independent populations of interneurons: (1) PV,
(2) SST/CB, and (3) CR/VIP expressing interneurons (Somogyi
et al., 1998).
Further, different subtypes of interneurons have different spa-
tial and temporal origins. The neocortical interneuron population,
as such, is derived from transient ventral telencephalic struc-
tures referred to as the ganglionic eminences as well as from
the preoptic area (Batista-Brito and Fishell, 2009; Gelman and
Marín, 2010). The medial ganglionic eminence (MGE) produces
∼70% of neocortical interneurons, including the PV-expressing
and SST-positive interneurons. Meanwhile, the caudal ganglionic
eminence (CGE) gives rise to a more heterogeneous group of cor-
tical interneurons that share the expression of 5HT3A ionotropic
serotoninergic receptors and are thus highly responsive to the neu-
romodulatory effects of serotonin (Batista-Brito and Fishell, 2009;
Gelman and Marín, 2010; Lee et al., 2010).
Another striking characteristic of GABAergic interneurons
is that different subtypes innervate distinct domains of the
postsynaptic glutamatergic cells. For example, SST/CB express-
ing interneurons selectively innervate distal dendrites of target
neurons, while PV-expressing, fast-spiking interneurons can be
divided in two major classes, basket cells which selectively inner-
vate the soma and proximal dendrites and chandelier cells, which
selectively innervate the axon initial segment of pyramidal cells
(Huang et al., 2007). The spatial organization of GABAergic
synapses along glutamatergic neurons has provided important
clues as to the speciﬁc functions of various interneuron subtypes
(Huang et al., 2007; Rossignol, 2011).
To truly understand how GABAergic circuits develop and func-
tion, it is essential to differentiate between distinct GABAergic
interneuron subtypes. It is indeed likely that speciﬁc interneuron
types differentially contribute to network processing that underlies
cortical functions ranging from perception to cognition. Conse-
quently, we can hypothesize that deﬁcits in speciﬁc interneuron
classesmay account, at least in part, for different neuropathological
conditions.
Recent technical advances have signiﬁcantly accelerated
progress in the interneuron ﬁeld. In particular, the development
of genetic strategies based on interneuron cell type-speciﬁc pro-
moters in combination with inducible Cre-loxP knockin driver
lines and ﬂuorescent protein reporter lines has allowed efﬁcient
high-resolution labeling and manipulation of speciﬁc GABAer-
gic interneuron classes in intact or “semi-intact” tissues (such
as organotypic brain cultures; Chattopadhyaya et al., 2004, 2007;
Taniguchi et al., 2011). Due to the availability of these new tools,
it is now possible to study speciﬁc GABAergic interneuron types,
from cell fate speciﬁcation, migration, and connectivity, to their
function in network dynamics and behavior. Combining insights
obtained from basic biological research on GABAergic interneu-
ron development, plasticity, and function with genetic and clinical
ﬁndings will provide us a detailed picture of the molecular events
that result in diseases characterized by GABAergic dysfunction,
and will suggest putative useful methods for targeted corrective
intervention.
GABAergic ALTERATIONS IN NEURODEVELOPMENTAL
DISEASES
SCHIZOPHRENIA
Schizophrenia is a severe brain disorder that afﬂicts 0.5–1% of
the world’s population and is usually ﬁrst diagnosed in late ado-
lescence or early adulthood. The illness manifests with three
classes of symptoms: positive or psychotic symptoms (i.e., delu-
sions, hallucinations, and disorganization of thought), negative
symptoms (i.e., ﬂat affect, avolition, and alogia), and cognitive
impairments such as abnormalities in working memory, inferen-
tial thinking, selective attention, as well as defects in executive
functions, linguistic ﬂuency, and social-emotional processing.
Although positive symptoms presents themost prominent clin-
ical feature of schizophrenia, disturbances in cognition appear to
be the core feature of the illness as they are present before the onset
of psychosis and are the best predictor of long-term functional out-
come for schizophrenia patients. Therefore, understanding neural
mechanisms underlying cognitive and dysfunctions is critical to
develop new therapeutic strategies particularly given that cur-
rently approved pharmacological treatments for schizophrenia are
largely ineffective at improving cognition.
A central cognitive deﬁcit in schizophrenia is the dysfunction
of working memory, i.e., the ability to store information and use it
while performing complex tasks (Baddeley, 2010). Gammaoscilla-
tions (30–80Hz) are thought to play an important role in normal
working memory because gamma band synchrony increases with
increasingworkingmemory load (Howard et al., 2003). In patients
with schizophrenia, working memory deﬁcits are accompanied
by altered patterns of cortical oscillatory activity. In particular,
gamma activity does not augment with increasing working mem-
ory load in schizophrenia patients (Basar-Eroglu et al., 2007;
Barr et al., 2010; Haenschel and Linden, 2011). Working mem-
ory related gamma activity, but not theta activity, is reduced in
the frontal cortex of ﬁrst-episode schizophrenia patients inde-
pendent of medication status, suggesting a deﬁcit related to the
disease process as opposed to medication side effects or as a
consequence of being chronically ill (Minzenberg et al., 2010).
Moreover, subjects with schizophrenia have decreased oscillations
in various frequency bands during speciﬁc phases of the working
memory process including encoding, maintenance, and retrieval
(Haenschel et al., 2009).
Among the several mechanisms proposed to play a role in
the generation of synchronized oscillations in neocortical circuits,
computationalmodeling studies, and numerous experimental evi-
dence support a leading role of GABA-mediated inhibition. In par-
ticular, convergent evidence indicates that synchronous activity in
PV-expressing, fast-spiking basket interneurons is key to the emer-
gence of gamma oscillations (Bartos et al., 2007). In vitro studies
in rodent hippocampus and cortex show that blocking GABA sup-
presses gammaoscillations, and that driving fast-spiking interneu-
rons by activating metabotropic glutamate receptors generates
gamma oscillations (Whittington et al., 1995; Bartos et al., 2002).
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Correlative in vivo studies similarly show that fast-spiking cells ﬁre
action potentials in phase with the gamma oscillations in the neo-
cortex (Hasenstaub et al., 2005; Sirota et al., 2008). Causal evidence
for this hypothesis in vivo has been recorded in the neocortex using
optogenetics, which allow the bidirectional modulation of neu-
ronal activity of selective cell populations that have beenmade sen-
sitive to light by geneticmanipulation.Optogenetic-mediated acti-
vation of PV-expressing interneurons selectively ampliﬁes gamma
oscillations and modulates sensory responses in rat somatosen-
sory cortex (Cardin et al., 2009). Conversely, suppressing PV-
expressing interneuron activity with optogenetic methods sig-
niﬁcantly reduced or abolished gamma oscillations (Sohal et al.,
2009). Finally,mice lackingNMDAR-mediatedneurotransmission
only in PV-expressing interneurons show altered cortical gamma
rhythmswith largely normal behavior except for selective cognitive
impairments, including deﬁcits in habituation, working memory,
and associative learning (Carlén et al., 2011). Therefore,GABAAR-
mediated currents from PV-expressing basket cells appear to be
the main source of GABA-mediated synchronization underlying
cortical gamma oscillations.
In parallel, evidence from post-mortem studies of brains of
subjects with schizophrenia supports the notion that speciﬁc
alterations in GABAergic interneurons are associated with this
disease (Lewis et al., 2005). In particular, one of the most reli-
able ﬁndings in schizophrenia research is the decrease in mRNA
for GABA-synthesizing enzyme GAD67, which appears to be
markedly deﬁcient in PV-positive interneurons in schizophrenic
brains (Hashimoto et al., 2003; Lewis et al., 2005). In addition, sev-
eral GABA-related transcripts including those for GAD67, PV, the
GABA transporter GAT1, SST, and the GABAAR subunits α1 and
δ, are decreased in dorsolateral PFC aswell as in the anterior cingu-
late, primary motor, and primary visual cortices (Hashimoto et al.,
2008). Overall these data suggest that disturbances in GABAergic
neurotransmission in speciﬁc cell types could represent a com-
mon pathological mechanism for different domains of cortical
dysfunction in schizophrenia. It is therefore possible that phar-
macological agents with the appropriate speciﬁcity for certain
GABAergic synapses might be effective for a range of clinical fea-
tures in the illness. While direct demonstration of a decrease in
GABA-mediated synaptic transmission, in particular from basket
cells, in the cortex of subjectswith schizophrenia is challenging and
still missing, the evidence available at the moment strongly points
toward a direct link between PV-positive basket cell dysfunction,
gamma oscillation alterations, and working memory deﬁcits in
schizophrenia patients.
Understanding PV-positive basket cell development in nor-
mal conditions should indicate the natural events occurring
during this process and point out potential pathogenic mech-
anisms that can cause GABAergic dysfunction and schizophre-
nia. GABAergic interneuron development is a prolonged process,
which starts in the embryo, progresses through childhood, and
is completed by adolescence in all mammalian species studied
including rodents and humans. During this prolonged period,
the interplay between genetic, epigenetic, and environmental fac-
tors can produce subtle developmental alterations in GABAer-
gic circuits that may contribute to the pathophysiology of
schizophrenia.
While themolecularmechanisms regulating postnatal develop-
ment of basket cells are not yet fully understood, recent papers have
started to address this issue. In particular, it has been shown that
the maturation of perisomatic innervation from GABAergic bas-
ket cells is modulated by neuronal activity and sensory experience
during a critical postnatal period (Chattopadhyaya et al., 2004;
Chattopadhyaya, 2011). A crucial factor regulating the develop-
ment of innervation patterns by basket cells is GABA release itself,
which regulates both the number of postsynaptic targets, as well as
the number of synapses made onto each target by a single basket
cell, in an age-dependent manner (Chattopadhyaya et al., 2007;
Baho and Di Cristo, 2012; Wu et al., 2012). In particular, GAD67
knockdown in single basket cells dramatically decreases the forma-
tion of terminal axon branches and perisomatic synapses, as well
as the number of postsynaptic neurons innervated by each bas-
ket cell (Chattopadhyaya et al., 2007). This ﬁnding is particularly
interesting since polymorphisms in the 5′ region of the Gad1 gene
(coding for GAD67) have been associated with decreased GAD67
and schizophrenia (Addington et al., 2005; Straub et al., 2007).
One possibility, therefore, is that altered inhibitory transmission
caused by the genetic impairment of GAD67 gene early in devel-
opment might alter the developmental trajectory of GABAergic
neural circuit maturation, thus causing global network alterations
predisposing to schizophrenia.
Another remarkable study showed that the trophic factor
Neuregulin-1 and its receptor ErbB4, which are both schizo-
phrenia susceptibility genes, regulate the development of PV-
positive basket cell synapses (Fazzari et al., 2010). Further,Neureg-
ulin signaling facilitates activity-dependent GABA release from
mature basket cells and selective loss of ErbB4 in these cells
causes a disinhibition of prefrontal pyramidal cells and results
in schizophrenia-relevant phenotypes in mice (Wen et al., 2010).
In another study, the polysialylated form of the neural cell
adhesion molecule NCAM has been shown to regulate the timing
of perisomatic GABAergic synapse maturation in mouse cortex
(Di Cristo et al., 2007). NCAM is polysialylated by two poly-
sialyltransferases ST8SiaII and ST8SiaIV. SNPs in ST8SIaII have
been implicated in schizophrenia (Arai et al., 2006; Tao et al.,
2007; Isomura et al., 2011), providing a mechanism by which
genetic interference with the complex coordination of NCAM
polysialylation and GABAergic synapse maturation may lead to
a neurodevelopmental predisposition to psychiatric disease.
In summary, multiple lines of evidence both in humans and
animals suggests that the development and function of PV-
expressing interneuron are particularly affected in schizophrenia.
How can we use this knowledge to design novel targeted ther-
apeutic approaches? Understanding the mechanisms underlying
PV-expressing basket cell synapse development and plasticity may
give us tools to modulate their function. Further, it has been pro-
posed that combining pharmacological tools to enhance neural
synchrony mediated by PV-positive basket cells along with behav-
ioral therapies involving learning paradigms to reduce or reverse
the consequences of altered neuronal circuit development could
be an effectivemeans of improving cognitive control in individuals
with schizophrenia (Gonzalez-Burgos et al., 2011; Lewis, 2011). It
is however important to underline that basket neurons are not
the only ones affected in schizophrenia and future efforts are
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needed to understand how alterations in speciﬁc circuits give rise
to associated cognitive impairments.
AUTISM
Autism is a complex neurodevelopmental disorder characterized
by abnormal socialization, deﬁcits in verbal and non-verbal com-
munication,anda limited interest in the surrounding environment
associated with stereotyped and repetitive behaviors. The inci-
dence of this disorder, which varies between 10 and 20 per 10000
children, has risen dramatically over the past two decades mainly
because of the use of broader diagnostic criteria and the increased
attention of the medical community (Levy et al., 2009). Clini-
cal signs are usually present at the age of 3 years, but prospective
studies of infants at risk have demonstrated that deﬁcits in social
responsiveness and communication could already be present as
early as 6–12months.
A high concordance rate between monozygotic twins (∼70%)
and a signiﬁcant sibling risk suggests that autism has a strong
genetic component (Bailey et al., 1995). Although there is a clear
genetic basis to autism, the majority of cases have unknown causes
(non-syndromic autism). Similar to other complex brain diseases,
it is likely that inherited risk factors, in combination with certain
environmental or epigenetic triggers, ultimately causes autism.
For many human diseases, the generation and characterization of
animal models is an essential bridge between understanding the
biological features of the disease and the development of targeted
therapeutic approaches. Thehigh genetic inheritanceof autismhas
resulted in the generation of several animal models, however their
validation has been controversial. Indeed, in the case of autism,
modeling human symptoms requires rigorous behavioral tests to
examine socialization, communication, and repetitive behavior,
which are rather difﬁcult to do in mice.
The majority of autism research has focused on the higher
cognitive symptoms, however, its important to consider that the
development and proper execution of higher cognitive processes
depends on basic primary processing. The behaviors typically
altered in autism arise from multiple sensory areas; for example,
communication and socialization involve parallel auditory, visual,
and somatosensory informationprocessing.Recent studies suggest
that altered low-level perceptual information processing is one of
the main problems in autism, and this affects higher integrative
areas of the brain (Bertone et al., 2003; Belmonte et al., 2004). Sys-
tematic developmental studies in autistic, high-risk infant siblings
and control subjects are necessary to better understand the role of
sensory processing and perception in the pathogenesis of autism.
Nevertheless, these studies suggest that testing sensory processing
in mouse models of autism is a promising approach that could
allow for a better understanding of the biological features altered
in the autistic brain.
Studies in autistic patients strongly suggest a correlation with
dysfunction in the GABAergic system. For example, analysis of
post-mortem tissues from autistic patients has shown that the
GABA-synthesizing enzymes GAD65 and GAD67 are signiﬁcantly
reduced (∼50%) in the parietal cortex and cerebellum (Fatemi
et al., 2002; Yip et al., 2007). Multiple studies have also found both
GABAA and GABAB receptor alterations in autistic brains (Collins
et al., 2006; Fatemi et al., 2009, 2010; Oblak et al., 2010). Reduced
benzodiazepine binding to hippocampal GABAA receptors further
suggests altered modulation of GABAA receptors in the presence
of GABA (Guptill et al., 2007). The cortex is organized in vertical
mini columns of functionally related glutamatergic and GABAer-
gic neurons that process thalamic inputs. Local GABAergic circuits
contribute to control the functional integrity of minicolumns via
lateral inhibition. Interestingly, the number of mini columns is
increased while their width is decreased in autistic brains indi-
cating abnormal cortical organization regulated by inhibitory
circuitry (Casanova et al., 2003). Further, a meta-analysis study
of PV expression across multiple autism mouse models found
a consistent reduction of PV-positive cells in the neocortex of
autism mouse models as compared to controls (Gogolla et al.,
2009). Maybe one of the most convincing indications of altered
GABAergic function in autism is the high co-morbidity of autism
with epilepsy.AlteredGABA functionmay reduce the threshold for
developing seizures. Indeed, ∼30% of autistic patients also have
epilepsy, and inter-ictal epileptic activity recorded on scalp EEG
occurs in up to 85% of autistic children (Gillberg and Billstedt,
2000; Yasuhara, 2010).
Non-idiopathic autism has been difﬁcult to study because of
the lack of suitable animal models. By comparing the molecu-
lar mechanisms underlying different single-gene disorders, it may
be possible to discover commonalities and general principles that
might hold true even for those cases in which no speciﬁc genetic
cause has been identiﬁed. Dysfunction of GABAergic signaling
has been shown to occur in the majority of animal models of
autism obtained by experimentally manipulating candidate genes
for autism susceptibility. Here, we summarize the GABAergic dys-
functions found in animal models carrying either rare mutations
identiﬁed in autism patients or mutations known to cause diseases
that are comorbid with autism. In fact, autism is comorbid with
a number of other diseases, including Rett and Angelman Syn-
drome, which have known genetic causes and have been modeled
in transgenic mice.
Mutations in neuroligin-neurexin adhesion complex
A small percentage of autistic patients carry single mutations
in genes encoding for synaptic cell adhesion molecules of the
neurexin (NRXN)-neuroligin (NLG) families. These include
mutations in genes encoding for NRXN1 (Szatmari et al., 2007;
Kim et al., 2008), NLG3, and NLG4 (Jamain et al., 2003; Laumon-
nier et al., 2004). Neuroligins are postsynaptic transmembrane
molecules localized at both excitatory and inhibitory synapses,
where they bind with presynaptic neurexins. Neuroligin-neurexin
complex has been shown to regulate the formation of both exci-
tatory and inhibitory synapse (for a review see Craig and Kang,
2007; Huang and Scheiffele, 2008; Südhof, 2008). In particu-
lar, a point mutation (R451C) that replaces an arginine with a
cysteine in the extracellular portion of neuroligin-3 was identi-
ﬁed in two brothers, one with severe autism and the other with
Asperger syndrome (Jamain et al., 2003). In addition, a mutation
inneuroligin-4has beendiscovered in another set of autistic broth-
ers (Jamain et al., 2003). Interestingly, mice carrying the mutation
R451C show an upregulation of inhibitory markers, including
the vesicular GABA transporter (VGAT) and the postsynaptic
scaffolding protein gephyrin. Further, inhibitory transmission in
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the somatosensory cortex is functionally augmented as shown
by increased frequency of miniature IPSCs, increased ampli-
tude of evoked IPSCs, and increased IPSC amplitude in response
to GABA application. Mutant mice show behaviors relevant to
autism, including altered socialization and enhanced spatial learn-
ing (Tabuchi et al., 2007; but see also Chadman et al., 2008).
However, none of these molecular, physiological, and behavioral
phenotypes were found in neuroligin-3 knockout mice, suggesting
that this particular mutation results in a gain-of-function though
the mechanism is still not well understood. In addition,mice lack-
ing neuroligin-4 show lack of reciprocal social interaction and
reduced ultrasonic vocalization, providing further evidence that
mutant neuroligin mouse models may be useful to study neuronal
circuit alterations in autism (Jamain et al., 2008).
Rett syndrome
Mutations in the X-linked MeCP2 gene, which encodes the tran-
scriptional regulator methyl-CpG-binding protein 2 (MeCP2),
causes the majority of Rett syndrome the majority of Rett syn-
drome cases. Rett syndrome is characterized by an apparently
normal early development followed by developmental regression,
including loss of language skills, motor abnormalities, cogni-
tive deﬁcits, stereotyped behavior, respiratory dysrhythmias, and
seizures sometimes leading to premature death.
To uncover the molecular changes that underlie Rett syn-
drome, mouse models with different MeCP2 mutations have been
generated. The analysis of synaptic circuit structure and func-
tion in these mouse lines showed several defects in the forma-
tion/maturation of neuronal GABAergic connectivity, which seem
to be speciﬁc to selected brain regions, including the ventro-lateral
medulla, the ventral basal complex, the reticular thalamic nucleus,
and the cerebellum (reviewed in Boggio et al., 2010). Interest-
ingly, wildtype GABAergic neurons express 50% more MeCP2
than wildtype non-GABAergic cells. Based on this observation,
a conditional mutant mouse was generated where MeCP2 was
exclusively disrupted in GABAergic cells using aVGAT-Cre mouse
line. These mice develop nearly all of the symptoms that arise
in germline MeCP2 knockout mice, including limb clasping, self-
injury from excessive grooming,motor deﬁciencies, increased pre-
pulse inhibition, altered socialization, and decreased lifespan. Fur-
ther,GABAergic neurons, in thesemice, exhibit reduced inhibitory
quantal size, reduced GAD65 and GAD67 levels, and reduced
GABA immunoreactivity. In addition, speciﬁc knockout of MeCP2
in forebrain GABAergic neurons recapitulates many of the symp-
toms observed in germline MeCP2 knockout mice (Chao et al.,
2010), therefore suggesting that disruption of MeCP2 exclusively
in inhibitory neurons is sufﬁcient to cause Rett syndrome in mice.
Angelman syndrome
Linkage and association studies have revealed that the chromoso-
mal region 15q11-q13 is strongly implicated in autism spectrum
disorders (Shao et al., 2003). Maternal duplications of this region
remains oneof themost commoncytogenetic abnormalities found
in cases of idiopathic autism, which account for 1–2% of the total
cases. Deletion of this region results in either Angelman or Prader-
Willi syndrome, depending on which parent the deletion comes
from. Within this chromosomal region, there is a gene cluster
of GABAA receptors: Gabrb3, Gabra5, and Gabrg3, encoding for
β3, α5, and γ3 subunits, respectively. Individuals with 15q11–13
deletions usually have more severe epilepsy than those with more
speciﬁc mutations for example in the gene E3 ubiquitin ligase,
which are sufﬁcient to cause Angelman syndrome, but spares the
GABAAR gene clusters (Minassian et al., 1998). Among differ-
ent GABAA receptor genes, the targeted deletion of Gabrb3 gene,
encoding for the β3 subunit, leads to abnormalities in social behav-
ior, cognitive deﬁcits,motor stereotypes, and seizures, reminiscent
of the autistic phenotype (DeLorey et al., 1998).
In summary, numerous studies both in human and animal
research suggests that GABAergic interneuron development and
function are affected in autism. It remains to be seen however,
whether these alterations are brain region and/or circuit speciﬁc
and most importantly, if they are a general feature of all autism
cases. So far autism is deﬁned as a “spectrum disorder” due to
the extraordinary heterogeneity of intellectual ability, associated
symptoms, and possible etiology. Future studies, therefore, are
critical to establish speciﬁc network alterations that are reliably
and consistently associated with the autism phenotype. Moreover,
the generation of animal models carrying human mutations will
be invaluable in dissecting the network, cellular, and molecular
changes underlying autism.
MODULATION OF GABAergic TRANSMISSION AS A TOOL TO
RESTORE PLASTICITY
Multiple lines of evidence critically implicate GABAergic dys-
function in neurodevelopmental diseases, including schizophrenia
and autism. It is important to note that alterations in GABAer-
gic functions are most likely not limited to these disorders. For
example, a mouse model of neuroﬁbromatosis Type 1, a neu-
rodevelopmental disorder associated with cognitive impairments,
including difﬁculties with visuospatial skills and executive func-
tion, as well as an increased incidence of autism, shows increased
GABA release,which underlies LTP and learning deﬁcits (Cui et al.,
2008). These ﬁndings open the question as to whether rescuing
speciﬁc GABAergic defects might ameliorate at least in part the
cognitive deﬁcits. Since the GABAergic network is truly heteroge-
nous with distinct GABAergic cell types, and multiple GABAergic
receptor isoforms, further studies are essential to develop a tar-
geted approach toward a speciﬁc class of GABAergic cells or/and
its associated speciﬁc cognitive function(s).
Altered GABA function, caused either by genetic/epigenetic or
environmental factors, or most likely by a combination of the
above, affects the developmental trajectory of interneuron con-
nectivity (Chattopadhyaya et al., 2007; Baho and Di Cristo, 2012;
Wuet al., 2012). In turn, the formationof interneuron connectivity
during early development is critical to the emergence of optimal
network architecture that subserve different cognitive functions in
the adult brain. Therefore it is likely that factors that cause the ini-
tial perturbation in GABAergic circuits would consequently affect
the processing of incoming sensory stimuli and drive the develop-
mental process along an abnormal trajectory. This leads to impor-
tant, recurrent questions for the appropriate therapeutic strategies:
What is the developmental window of opportunity for pharma-
cological treatment of neurodevelopmental diseases? Can existing
symptoms be corrected or improved, or is it necessary to initiate
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treatment early in pre- or postnatal development prior to the onset
of symptoms? In other words, is it possible to change abnormal
neuronal circuits after their formation and consolidation? Recent
studies aiming at reversing cognitive and neural circuit deﬁcits
using genetic, pharmacological, or environmental strategies in dif-
ferent mouse models of neurodevelopmental diseases have shown
encouraging results. For example, in a mouse model of Rett syn-
drome,MeCP2 function was restored during or following onset of
symptoms using a tamoxifen-inducible Cre-LoxP strategy, result-
ing in the robust reversal of several associated phenotypes (Guy
et al., 2007). Further, early enriched environment starting before
the second postnatal week dramatically improved several pheno-
types of MeCP2 mutant mice (Lonetti et al., 2010). In addition,
pharmacological treatments have been shown to improve mem-
ory impairments inmousemodels of Tuberous Sclerosis (Ehninger
et al., 2008; Auerbach et al., 2011) or Fragile X Syndrome (Krueger
and Bear, 2011). All together, these studies constitute an important
proof of principle that the course of neurodevelopmental diseases
could be arrested and even reversed with manipulations begun in
late childhood and early adolescence, at least in animal models.
Although the human brain retains plasticity through life, con-
tinuously reorganizing its connections in the face of new expe-
riences, the foremost period of heightened plasticity is during
childhood when there exist “critical periods” during which expe-
rience can produce permanent, large-scale changes in neuronal
circuits. Understanding the mechanisms that underlie activation
and regulation of such critical periods in the central nervous sys-
tem may help us develop rational pharmacological approaches
to correct alterations in the brain of children with neurodevel-
opmental disorders involving altered synapse formation and/or
plasticity.
The most widely studied model of experience-dependent plas-
ticity is ocular dominance (OD)plasticity in the visual cortex. Elec-
trophysiological recordings from neurons in the primary visual
cortex show activation to different degrees by visual stimuli pre-
sented to one eye or the other, a property termed OD. Closing one
eye during a speciﬁc postnatal time period causes synaptic reor-
ganization of neural circuits in visual cortex, resulting in lifelong,
irreversible reduction of the ability of the deprived eye to drive
neuronal responses in the cortex, and an increase in the number of
neurons responsive to stimuli presented to the open eye. This time
period speciﬁc change in eye preference following manipulation
of visual inputs is called OD plasticity (Hubel and Wiesel, 1970).
In adults, however, such plasticity in OD, while not eliminated, is
strongly restricted.
Convergent studies show that development of inhibitory cir-
cuitry in the cortex is critical for controlling the onset and time
course of critical periods. For example, the onset of visual corti-
cal plasticity is delayed by genetic disruption of GABA synthesis
(Hensch et al., 1998). In parallel, application of benzodiazepines
or other treatments that accelerate GABA circuit function triggers
premature plasticity (Huang et al., 1999; Fagiolini and Hensch,
2000; Di Cristo et al., 2007). Further, recent results implicate
intracortical inhibition as a fundamental limiting factor for adult
cortical plasticity. In adult animals, where inhibitory circuits are
fully developed, a brief reduction of GABAergic inhibition is sufﬁ-
cient to reopen a window of plasticity in the visual cortex well after
the normal closure of the critical period (Harauzov et al., 2010). In
addition different pharmacological and environmental strategies
shown to enhance plasticity in the adult visual cortex, act at least
in part, through a reduction of GABAergic inhibition (Sale et al.,
2007; Maya-Vetencourt et al., 2008).
In an elegant study, Southwell et al. (2010) showed that trans-
planted MGE GABAergic precursors are sufﬁcient to trigger a
plasticity response in the host cortex of young mice. Interestingly,
grafted interneurons promote plasticity only when they reach a
cellular age comparable to that of the endogenous counterpart
during the critical period, suggesting that plasticity is successfully
initiated by a cell-autonomous program present in interneuron
progenitors and is minimally inﬂuenced by the age of the host
tissue. It is still unknown, however, whether transplantation of
interneurons could induce visual plasticity in adults; nevertheless
these ﬁndings suggest that cell transplantation might be effective
in triggering plasticity processes.
In addition to GABAergic inhibition, several other factors have
been implicated in limiting adult plasticity (Pizzorusso et al., 2002;
McGee et al., 2005; Syken et al., 2006; Bavelier et al., 2010; Mor-
ishita et al., 2010). Therefore, targeting multiple pathways maybe
key to successfully increase plasticity in the adult brain at a level
sufﬁcient enough to trigger long-lasting neural circuitry reorgani-
zation. Further along the road, coupling cognitive rehabilitation
with pharmacological treatments that facilitate brain plasticity,
could correct neuronal network connectivity and function and,
ultimately, improve cognitive deﬁcits.
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